Details for Patent: 10,011,637

Which drugs does patent 10,011,637 protect, and when does it expire?

Patent 10,011,637 protects TRULANCE and is included in one NDA.

This patent has sixteen patent family members in eleven countries.

Summary for Patent: 10,011,637

Title:	Ultra-pure agonists of guanylate cyclase C, method of making and using same
Abstract:	The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
Inventor(s):	Shailubhai; Kunwar (Audubon, PA), Comiskey; Stephen (Doylestown, PA), Feng; Rong (Langhorne, PA), Bai; Juncai (North Augusta, SC), Zhang; Ruoping (North Augusta, PA), Jia; Jun (Shanghai, CN), Zhou; Junfeng (Shanghai, CN), Zhao; Qiao (Shanghai, CN), Zhang; Guoqing (Shanghai, CN)
Assignee:	SYNERGY PHARMACEUTICALS, INC. (New York, NY)
Application Number:	14/896,019
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,011,637
Patent Claim Types: see list of patent claims	Compound; Process;

Drugs Protected by US Patent 10,011,637

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745-001	Jan 19, 2017		RX	Yes	Yes				Y

International Family Members for US Patent 10,011,637

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014274812
Australia	2018226473
Australia	2020205349
Brazil	112015030326
Canada	2913737
China	105764916